Join to access to all OVN content. Join for Free
Motivation Means NOTHING…
Medical Science Liaisons discipline in Medical Affairs achieving goals personal growth strategies success in MSL roles

Motivation Means NOTHING…


Share This Article


Summary

In this episode, Tom Caravela delves into the crucial role of discipline for Medical Science Liaisons. He outlines a four-step process to help MSLs achieve their goals within Medical Affairs, emphasizing the importance of starting small and maintaining a zero-compromise mentality. Tom underscores the significance of discipline in driving success and personal growth. The episode wraps up with a call to action, inviting listeners to incorporate these strategies into their professional lives.

This SOLO episode features Tom Caravela, Managing Partner at The Carolan Group sharing his thoughts on WHY motivation means NOTHING and what it takes to find success and achieve your goals
Tom shares….

👉 WHY motivations means nothing
👉 What it takes to find consistent success
👉 The formula for consistency
👉 How to ACHIEVE and find success at the highest levels

Click for Source
Medical Science Liaisons, discipline in Medical Affairs, achieving goals, personal growth strategies, success in MSL roles

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Explore OVN